Fragment 176-191 & CJC-1295 & Ipamorelin – 12MG

Scientific Overview of Fragment 176-191, CJC-1295 & Ipamorelin

Fragment 176-191, also known as hGH Fragment 176-191, Frag 176-191, AOD 9604, or tyr-hGH 177-191, represents the proposed “lipolytic fragment” of human growth hormone. It has been studied in relation to fat metabolism and thermogenesis.

CJC-1295, sometimes referred to as a growth hormone–releasing hormone (GHRH) analog, is a modified version of GHRH (1-29) designed for extended stability in laboratory settings.

Ipamorelin is classified as a growth hormone secretagogue receptor (GHSR) agonist and is often compared to other GHRPs, while being noted for its apparent selectivity in laboratory observations.

Fragment 176-191, CJC-1295 & Ipamorelin Studies and Research Data

Fragment 176-191, CJC-1295 & Ipamorelin Research on Fat Metabolism

Fragment 176-191 has been investigated for its possible influence on lipid breakdown in adipose tissue and the promotion of thermogenesis in skeletal muscle. In animal models, findings suggest stronger responses in obese specimens compared to lean ones. Some studies have also indicated potential roles in cartilage regeneration and immune-related pathways.

Growth Hormone Signaling Studies

CJC-1295 has been reported to elevate mean plasma growth hormone concentrations several-fold, while also suggesting increases in insulin-like growth factor-1 (IGF-1) levels. Research in GHRH-deficient murine models suggests that CJC-1295 may help maintain standard growth, lean mass, and body length. It also appeared linked to increased pituitary RNA and GH mRNA levels, suggesting a possible expansion of somatotroph cells.

Findings on Bone and Mineral Pathways

Ipamorelin has been studied for possible effects on bone mineralization and density. Observations in rodent studies suggest that increases in bone mineral content may reflect structural adaptations, rather than changes in volumetric bone density. This peptide has also been studied in relation to osteoblast activity, tibial development, and vertebral structure.

Fragment 176-191, CJC-1295 & Ipamorelin Investigations of Synergistic Actions

When studied together, Ipamorelin and CJC-1295 appear to demonstrate complementary dynamics in laboratory models. Ipamorelin may trigger rapid, short-term growth hormone release, whereas CJC-1295 may sustain longer-term patterns. This combination has been explored as a means to replicate both immediate and extended growth hormone signaling.

Conclusion

Research into Fragment 176-191, CJC-1295, and Ipamorelin suggests possible influences on fat metabolism, growth hormone regulation, musculoskeletal processes, and bone-related pathways. These observations remain preliminary, with more research needed to clarify their significance.

References

1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4.
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9.
3. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6.
4. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805.
5. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8.
6. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77.
7. Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M. Combined effects of oleoyl-estrone and a beta3-adrenergic agonist on lipid stores of diet-induced overweight male Wistar rats. Life Sci. 2005 Sep;77(16):2051-8.
8. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
9. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6.
10. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan;51(1):73-84.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.